Peptisyntha Inc. has started the next expansion of its cGMP-compliant manufacturing facilities in Torrance, California. The first phase of this expansion program will be completed by the end of 2008. This new expansion at Peptisyntha Inc. reflects the need for additional lab and office space based on the double-digit growth enjoyed by the company since its inception, with the production of peptides in solid phase for clinical or commercial use.
This expansion of the cGMP production capacity in Torrance, California, complements ongoing investments in the production operations of the liquid phase peptide synthesis capacity at Peptisyntha SA in Brussels, Belgium.
The peptide business makes a significant contribution to the overall platform of technologies of Solvay Organics, a business unit focused on high added value organic chemical specialties serving a wide array of market segments with innovative molecules, materials and solutions for novel applications.
Peptisyntha SA and Peptisyntha Inc. are fully owned subsidiaries of the Solvay Group. Details are available at www.peptisyntha.com.
Peptisyntha Inc. is a member of the Solvay Group, Solvay is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs more than 28,000 people in 50 countries. In 2007, its consolidated sales amounted to EUR 9.6 billion, generated by its three sectors of activity: Chemicals, Plastics and Pharmaceuticals. Solvay (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLB.BR) is listed on the NYSE Euronext stock exchange in Brussels. Details are available at www.solvay.com
